Navigation Links
GeneraMedix, Inc. Announces Sale of Innovative Epoprostenol Formulation to Actelion Ltd.
Date:2/23/2009

LIBERTY CORNER, N.J., Feb. 23 /PRNewswire/ -- GeneraMedix, Inc. announced today that it has entered into a definitive agreement to sell its improved formulation of epoprostenol sodium for the intravenous treatment of pulmonary arterial hypertension (PAH) to Actelion LTD., a biopharmaceutical company with its headquarters in Allschwil/Basel, Switzerland. Financial terms of the deal were not disclosed.

"This sale speaks directly to our company's ongoing commitment to serving the unique needs of patients in specialty markets, in this case pulmonary arterial hypertension (PAH)," said Ron Quadrel, CEO, of GeneraMedix, Inc. "I'm also very pleased to conclude this transaction with Actelion, a company that is committed to improving the lives of PAH patients through improved treatment options," added Quadrel.

On June 27, 2008, the U.S. FDA approved Epoprostenol for Injection (1.5 mg/ml vial) for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.

The new formulation of epoprostenol uses non-proprietary diluents, and once reconstituted prior to use, it may be stored for up to 48 hours at 25 degrees Celsius or for five days in the refrigerator at 2-8 degrees Celsius. Global patents have been filed for this new formulation. Actelion will be responsible for global development, registration and commercialization for the product.

"We are very pleased to acquire this innovative product as it builds on our commitment to PAH therapy. Actelion has always led the drive in developing innovative therapies for PAH patients and treating physicians, and we believe this new improved formulation could potentially play a significant role in the management of PAH," stated Jean-Paul Clozel, M.D. and CEO of Actelion.

Unlike other epoprostenol formulations approved for PAH, this unique formulation is stable at room temperature for up to 24 hours when diluted and filled into the pump for administration and so can be used without frozen gel packs.

"Having developed this specialty therapy for the PAH market is exciting and positively reflects on the GeneraMedix pipeline and growing reputation in specialty markets," said Robin Smith Hoke, President, Commercial Operations for GeneraMedix. "This deal is also the result of strong partnership with the team at Actelion as well as our equity partners GTCR Golder Rauner LLC, and Ferrer Freeman & Company, LLC."

Actelion Ltd

Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer(R), an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer(R) through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 1900 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI(R))

GeneraMedix, Inc.

GeneraMedix Inc. is a privately held pharmaceutical company specializing in difficult to develop and/or manufacture injectable products for the U.S. hospital and specialty markets. In addition to its marketed products, GeneraMedix has a significant number of injectable products under development, as well as a number of products currently under FDA review. Headquartered in Liberty Corner, New Jersey, the company was founded in July of 2004, with equity partners GTCR Golder Rauner, LLC, and Ferrer Freeman and Company. Additional information is available on the company's website at www.generamedix.com


'/>"/>
SOURCE GeneraMedix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries
2. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
3. Abbott Announces 11 Percent Increase in Quarterly Dividend
4. Shire Announces Opening of Office in Japan
5. InterMune Announces Issuance of U.S. Patent for ITMN-191
6. Lightwave Logic, Inc. Announces the Addition of Anthony J. Cocuzza, PhD to its Technology Team
7. Psychemedics Corporation Announces 2008 Year End Results
8. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
9. Amicus Therapeutics Announces Change to Board of Directors
10. Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2008 Earnings Release Conference Call Webcast
11. Obio Pharmaceutical Announces Product Growth Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, doctors ... being treated for breast cancer benefitted from an injection of stem cells derived from ... frequent side effect of cancer treatment. , Lymphedema refers to the swelling ...
(Date:6/23/2016)... -- Andrew D Zelenetz , ... Published recently in Oncology & ... Andrew D Zelenetz , discusses the fact ... placing an increasing burden on healthcare systems worldwide, ... the patents on many biologics expiring, interest in ...
(Date:6/23/2016)... ... 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), a ... webinar on Performing Quality Investigations: Getting to Root Cause. This ... charge. , Incomplete investigations are still a major concern to the Regulatory Authorities ...
Breaking Biology Technology:
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
Breaking Biology News(10 mins):